Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: WWS who wrote (203)	1/26/1999 3:04:00 PM
From: scaram(o)uche	Respond to of 805

Thanks, Bill. Clears up a lot. (eom)

To: WWS who wrote (203)	1/26/1999 3:33:00 PM
From: Mike McFarland	Respond to of 805

Vescovi research currently lies outside of the scope of their existing agreements with Neurospheres I had a feeling that would probably be true, nevertheless, I'll hang in there...after all, ctii isn't much above book value in here, so most likely only one way to go for the stock. With any luck we will here something in the next few months about the IIB pain trial with Astra, and anything more that comes of the stem cells will be gravy...a lot of gravy. In the 12/21 PR, Rose said "These licenses demonstrate our continued interest in complementary stem cell-related technologies to build upon our leadership position in the field of stem cell therapy" I guess after reading Rick's post I am reminded that there are a lot of dogs barking up this tree--but perhaps that will come into play if a larger player looks around and buys some intellectual property. Rick--I had a pretty good idea that a lot of this encapsulation and stem cell stuff was already out there...I had done the ol' recap query and done the minimum amount of DD;-) recap.com I figured a smattering of appearances on the list was good enough for me--maybe not for others, but I have an extremely high tolerance for risk. --Mike